Literature DB >> 29768723

Importance of choice of materials and methods in PD-L1 and TIL assessment in oropharyngeal squamous cell carcinoma.

Astrid De Meulenaere1, Tijl Vermassen1, David Creytens2, Sandrine Aspeslagh3, Philippe Deron4, Frederic Duprez5, Sylvie Rottey1, Jo A Van Dorpe2, Liesbeth Ferdinande2.   

Abstract

AIMS: A great deal of research is being conducted into PD-L1 immunohistochemistry (IHC) and tumour-infiltrating lymphocytes (TILs) as predictive or prognostic biomarkers for immunotherapy, although several practical issues exist concerning their assessment. The aim of this research was therefore to assess the importance of choice of materials and methods in PD-L1 and TILs scoring in oropharyngeal squamous cell carcinoma (OSCC). METHODS AND
RESULTS: IHC for PD-L1 (SP142 and 22C3 clone) and TILs subtyping was performed on formalin-fixed paraffin-embedded tissue slides (biopsy, resection and/or lymph nodes specimens) of 99 patients with OSCC. A comparative analysis of PD-L1 and TILs scoring was made between different types of tissue specimens, between different PD-L1 clones, between TILs and different subsets of TILs and between the quantitative and semiquantitative assessments. PD-L1 scoring resulted in fair to moderate agreement for 22C3 and SP142 between various tissue specimens, with higher agreement at higher cut-off values, and in moderate agreement for 22C3 versus SP142. Evaluation by four independent observers proved substantial inter-rater agreement for both clones with high consistency in their ratings. Moderate agreement was observed for TILs and TILs subsets for the comparison between biopsy and resection. Lastly, strong correlations were found between quantitative and semiquantitative assessment for all PD-L1 and TILs scores.
CONCLUSIONS: Our results highlight the challenges associated with the evaluation of PD-L1 and TILs in OSCC. Further research is warranted to evaluate the use of these biomarkers in order to allow implementation of PD-L1 and TILs infiltrate as biomarkers in daily clinical practice.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  PD-L1; biomarker; methodology; oropharyngeal squamous cell carcinoma; tumour-infiltrating lymphocytes

Mesh:

Substances:

Year:  2018        PMID: 29768723     DOI: 10.1111/his.13650

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.

Authors:  Sophie Outh-Gauer; Aurélien Morini; Eric Tartour; Charles Lépine; Alain C Jung; Cécile Badoual
Journal:  Head Neck Pathol       Date:  2020-03-02

2.  Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma.

Authors:  Sebastian Blatt; Maximilian Krüger; Constantin Rump; Stefanie Zimmer; Keyvan Sagheb; Julian Künzel
Journal:  PLoS One       Date:  2022-05-27       Impact factor: 3.752

3.  PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols.

Authors:  Simona Crosta; Renzo Boldorini; Francesca Bono; Virginia Brambilla; Emanuele Dainese; Nicola Fusco; Andrea Gianatti; Vincenzo L'Imperio; Patrizia Morbini; Fabio Pagni
Journal:  Cancers (Basel)       Date:  2021-01-14       Impact factor: 6.639

4.  Correlation between hematological parameters and PET/CT metabolic parameters in patients with head and neck cancer.

Authors:  Beat Bojaxhiu; Dubravko Sinovcic; Olgun Elicin; Arnoud J Templeton; Mohamed Shelan; Jan Wartenberg; Ian Alberts; Axel Rominger; Daniel M Aebersold; Kathrin Zaugg
Journal:  Radiat Oncol       Date:  2022-08-13       Impact factor: 4.309

5.  Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review.

Authors:  Emily A Prince; Jenine K Sanzari; Dimple Pandya; David Huron; Robin Edwards
Journal:  JCO Precis Oncol       Date:  2021-06-08

6.  High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature.

Authors:  Giuseppe Troiano; Vito C A Caponio; Khrystyna Zhurakivska; Claudia Arena; Giuseppe Pannone; Marco Mascitti; Andrea Santarelli; Lorenzo Lo Muzio
Journal:  Cell Prolif       Date:  2018-11-15       Impact factor: 6.831

7.  Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma.

Authors:  Maria Togo; Takehiko Yokobori; Kimihiro Shimizu; Tadashi Handa; Kyoichi Kaira; Takaaki Sano; Mariko Tsukagoshi; Tetsuya Higuchi; Satoshi Yokoo; Ken Shirabe; Tetsunari Oyama
Journal:  Br J Cancer       Date:  2020-04-02       Impact factor: 7.640

Review 8.  Quality Assessment Across Disciplines in Head and Neck Cancer Treatment Diagnostic Pathology in HNSCC.

Authors:  Philip Sloan; Max Robinson
Journal:  Front Oncol       Date:  2020-03-24       Impact factor: 6.244

Review 9.  Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?

Authors:  Alhadi Almangush; Stijn De Keukeleire; Sylvie Rottey; Liesbeth Ferdinande; Tijl Vermassen; Ilmo Leivo; Antti A Mäkitie
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.